Royal Harbor Partners’s AbbVie ABBV Stock Holding History

Royal Harbor Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,858	Closed	-$385K	–	49
2023 Q2	$385K	Hold	2,858	–	–	0.19%	59
2023 Q1	$455K	Hold	2,858	–	–	0.24%	57
2022 Q4	$462K	Hold	2,858	–	–	0.29%	53
2022 Q3	$384K	Hold	2,858	–	–	0.26%	62
2022 Q2	$438K	Buy	2,858 +20	+0.7%	+$3.06K	0.3%	53
2022 Q1	$460K	Buy	2,838 +20	+0.7%	+$2.9K	0.29%	59
2021 Q4	$382K	Hold	2,818	–	–	0.24%	62
2021 Q3	$304K	Buy	2,818 +50	+2%	+$5.71K	0.22%	68
2021 Q2	$312K	Hold	2,768	–	–	0.21%	64
2021 Q1	$300K	Hold	2,768	–	–	0.23%	59
2020 Q4	$297K	Hold	2,768	–	–	0.25%	71
2020 Q3	$242K	Hold	2,768	–	–	0.23%	72
2020 Q2	$272K	Hold	2,768	–	–	0.27%	71
2020 Q1	$211K	Hold	2,768	–	–	0.24%	67
2019 Q4	$245K	Buy	+2,768	New	+$230K	0.24%	53

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Royal Harbor Partners's ABBV Position: Q3 2023 in Review

Royal Harbor Partners sold out of AbbVie (ABBV) in Q3 2023, closing a stake of 2,858 shares — an estimated $385K sold.

Royal Harbor Partners first reported a position in ABBV in Q4 2019 and held it in 15 quarters. The position peaked at $462K in Q4 2022. 3,108 funds tracked by Wall St. Rank hold ABBV as of Q3 2023.

Royal Harbor Partners reported no remaining AbbVie position as of Q3 2023 after selling out during the quarter.
Royal Harbor Partners sold 2,858 AbbVie shares in Q3 2023, an estimated $385K.
Royal Harbor Partners first reported a position in AbbVie in Q4 2019 and held it in 15 quarters.
Royal Harbor Partners's AbbVie position peaked at $462K in Q4 2022.
3,108 funds tracked by Wall St. Rank held AbbVie as of Q3 2023.

Based on Royal Harbor Partners's 13F filing for Q3 2023, filed 14 Nov 2023.